Irinotecan in the treatment of colorectal cancer: Clinical overview

Journal of Clinical Oncology

Volumn 19, Issue 5, 2001, Pages 1501-1518

  Vanhoefer, U ^a   Harstrick, A ^a   Achterrath, W ^a   Cao, S ^a   Seeber, S ^a   Rustum, Y M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CAPECITABINE; DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; RALTITREXED; SEROTONIN 3 ANTAGONIST; THYMIDYLATE SYNTHASE INHIBITOR; UFT;

ADULT; AGED; ASTHENIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG CYTOTOXICITY; DRUG INDUCED DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0035281522     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.5.1501     Document Type: Review

References (197)

1. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma
2. Thymidylate synthase inhibitors in cancer therapy: Direct and indirect inhibitors
3. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
4. DNA topoisomerases: Essential enzymes and lethal targets
5. Preclinical evaluation of CPT-11 and its active metabolìte SN-38
6. Eukaryotic DNA topoisomerase 1: Genome gatekeeper and its intruders, camptothecins
7. Irinotecan: A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer
8. Topoisomerase I inhibitors: Review and update
9. CPT-11 in gastrointestinal cancer
10. Camptothecins: A review of their development and schedules of administration
11. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
12. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
13. A randomized phase II trial assessing irinotecan (IRI) and 5FU/folinic acid (LV), "Mayo regimen", in first line palliative chemotherapy patients with metastatic colorectal cancer
14. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy
15. Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer resistant to 5-FU
16. Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer: Overall results of FDA-reviewed pivotal US clinical trials
17. Single-agent chemotherapy of colorectal cancer
18. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
19. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
20. DNA topoisomerases
21. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA
22. A model for the mechanism of human topoisomerase I
23. Human immunodeficiency virus type 1 reverse transcriptase: Enhancement of activity by interaction with cellular topoisomerase I
24. The promoter region of the human type-DNA-topoisomerase gene: Protein-binding sites and sequences involved in transcriptional regulation
25. Structural characterization of the human DNA topoisomerase I gene promoter
26. Structure of the human type I DNA topoisomerase gene
27. Expression of the type I DNA topoisomerase gene in adenovirus- 5 infected human cells
28. Variation in DNA swivel enzyme activity during the mammalian cell cycle
29. Gene expression in regenerating liver in relation to cell proliferation and stress
30. The human topoisomerase I gene promoter is regulated by NF-IL 6
31. Effects of DNA methylation on topoisomerase I and II cleavage activities
32. The ATM protein is required for sustained activation of NF-kappaB following DNA damage
33. Phosphorylation of mammalian DNA topoisomerase I and activation by protein kinase C
34. Protein kinase C phosphorylates DNA topoisomerase I
35. Topoisomerase I phosphorylation in vitro and in rapidly growing Novihoff hepatoma cells
36. Heat stress induces hsc70/nuclear topoisomerase I complex formation in vivo: Evidence for hsc70-mediated, ATP-independent reactivation in vitro
37. Modulation of DNA topoisomerase I activity by p53
38. A role for the amino terminus of human topoisomerase I
39. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-38), by human liver carboxylesterase
40. Metabolic activation of CPT-11, 7-ethyl-10-[4-(l-piperidino)-l-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase
41. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I
42. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin
43. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
44. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
45. Different fates of camptothecin-induced replication fork-associated double-strand DNA breaks in mammalian cells
46. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: Studies in a cell-free SV 40 DNA replication system
47. Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA
48. Microinjection of anti-topoisomerase I immunoglobulin G into nuclei of Chironomus tentans salivary gland cells leads to blockage of transcription elongation
49. Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes
50. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors
51. Therapeutic efficacy of the topoisomerase l inhibitor 7-ethyl-10-(4-[1-piperidino]l-piperidino]-carbonyloxy-camptothecin against human tumor xenografts: Lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl- 10-hydroxycamptothecin
52. Mechanism of action of camptothecin
53. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin
54. CPT-11 in human colon-cancer cell lines and xenografts: Characterization of cellular sensitivity determinants
55. Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity
56. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors
57. DNA topoisomerase I-targeted chemotherapy of human cancer in xenografts
58. Elevation of topoisomerase I mRNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy
59. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon
60. Topoisomerase I and 1I activity in human breast, cervix, lung and colon cancer
61. Gene mutation analysis and quantitation of DNA topoisomerase I in previously untreated non-small cell lung carcinomas
62. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy
63. No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer
64. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen
65. Human tumor carboxylesterase activity correlates with CPT-11 cytotoxicity in vitro
66. Dimerization of mitochondrial Bax is associated with increased drug response in Bax-transfected A 253 cells
67. Involvement of cyclin DI-CDK5 overexpression and MCM3 cleavage in bax-associated spontaneous apoptosis and differentiation in an A253 human head and neck carcinoma xenograft model
68. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma
69. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I
70. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine
71. Development of a stable camptothecin-resistant subline of P 388 leukemia with reduced topoisomerase 1 content
72. Mutation at the catalytic site of topoisomerase I in CEM/C 2, a human leukemia cell line resistant to camptothecin
73. Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I
74. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human nonsmall cell lung cancer: Characterization and mechanism of resistance
75. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin
76. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan
77. Decreased expression of DNA topoisomerase 1 in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody
78. Nonproductive rearrangement of DNA topoisomerase I and II genes: Correlation with resistance to topoisomerase inhibitors
79. Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA
80. The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro
81. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase 11 in a melphalan-resistant rhabdomyosarcoma xenograft that is crossresistant to nitrosoureas and topotecan
82. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines
83. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F104864), a new camptothecin analogue
84. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein
85. Antitumor efficacy of irinotecan (CPT-11) and topotecan in nude mice bearing tumor xenografts that express the multidrug resistance protein (MRP)
86. Reversal of MDRI-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines
87. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells
88. Reduced cellular accumulation of topotecan: A novel mechanism of resistance in a human ovarian cancer cell line
89. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations
90. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line
91. Camptothecin resistance: Role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells
92. Expression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinomas
93. The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers
94. High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: A phase II and pharmacodynamic study
95. Topotecan in colorectal cancer: A phase II study of the EORTC early clinical trials group
96. Phase II study with topotecan (T) administered as a 21-days continuous infusion to patients with colorectal cancer
97. Phase II study of 21-day topotecan continuous infusion for metastatic colorectal cancer (ECOG study 4283)
98. Phase II evaluation of topotecan in patients with advanced colorectal cancer
99. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro
100. Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT- 29 in vitro and in vivo
101. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line
102. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines
103. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN38) to 5-fluorouracil and folinic acid in HCT-8 cells: Elevated dTTP pools and enhanced cytotoxicity
104. Combination of irinotecan (CPT-11) and 5-fluorouracil with an analysis of cellular determinants of drug activity
105. New drugs in therapy of colorectal cancer: Preclinical studies
106. Schedule-dependent antitumor efficacy of irinotecan (CPT-11) in 5-FU resistant human colon tumor xenograft HT29RI
107. CPT-11/oxaliplatin (L-OHP) combination every two weeks: Final results of a phase I study in advanced digestive malignancies
108. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: Results of two independent phase I studies with pharmacokinetics
109. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN- 38 and the diaminocyclohexane platinum derivative oxaliplatin
110. Mechanism of synergy between oxaliplatin and the topoisomerase I inhibitor SN-38
111. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats
112. Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats
113. Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model
114. Phase I study of weekly intravenous infusions of CPT-11 a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer
115. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion
116. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients
117. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients
118. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors
119. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors
120. High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: A feasibility study
121. 2 given every-other-week in previously treated colorectal cancer patients
122. Phase I and pharmacokinetic trial of weekly CPT-11
123. Phase I and pharmacological study of the novel topoisomerase 1 inhibitor 7-ethyl-10-[4-(l-piperidino)piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks
124. Phase I study of chronic daily low-dose irinotecan (CPT-11)
125. Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients
126. Phase I clinical and pharmacokinetic study of 5 day CPT-11 hepatic arterial infusion (HAI) chemotherapy
127. Phase I and pharmacokinetic study of intravenous irinotecan (CPT-11) administered once every 2 weeks +/- G-CSF
128. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors
129. A phase I study of irinotecan in pediatric patients: A Pediatric Oncology Group study
130. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children
131. A phase I trial of irinotecan (CPT-11) in children
132. Irinotecan (CPT-11) in combination with high-dose infusional 5-FU (Ttd schedule) in advanced colorectal cancer (CRC): Preliminary results of a phase I/II study
133. A phase I and pharmacokinetic study of CPT-11 and 5-FU in combination
134. Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: A phase I study of the Southern Italy Cooperative Oncology Group
135. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dosefinding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer
136. Escalating dose irinotecan (CPT-11) immediately prior or after 5-fluorouracil (5-FU) 48 hours infusion + leucovorin (LV): Pharmacokinetic and pharmacodynamic interactions in chemotherapy-naïve metastatic colorectal cancer patients
137. Phase I study of the combination of CPT-11/5-FU and leucovorin (LV)
138. A phase I study of CPT-11 plus chrono-modulated (chrono) 5-fluorouracil (5-FU) and I-folinic acid (FA) in advanced colorectal cancer patients
139. Phase I study with irinotecan (CPT-11) plus 5-fluorouracil (5-FU; 4-DY C.I.) combination in advanced colon cancer
140. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors
141. Phase I dose finding study of irinotecan (CPT-11) over a short IV infusion combined with a fixed dose of 5-fluorouracil (5-FU) over a protracted IV infusion in patients with advanced solid tumors
142. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer
143. Extended phase I study of a weekly schedule of irinotecan (CPT-11), leucovorin and infusional 5-FU as first-line chemotherapy in metastatic colorectal cancer
144. Irinotecan in combination with leucovorin and 5-fluorouracil 48 hours continuous infusion: A phase I study with pharmacokinetic, DNA damage and topoisomerase I/DNA complexes evaluation in chemotherapy naïve metastatic colorectal cancer patients
145. Phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer
146. Open label dose finding phase I study of irinotecan hydrochloride and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma
147. Phase I and pharmacokinetic trial of irinotecan (CPT-11) and Tomudex administered as sequential IV infusions, D1 and D2, repeated every 21 days
148. A phase I clinical and pharmacokinetic trial of oxaliplatin and irinotecan (CPT-11) given every two weeks to patients with refractory solid tumors
149. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN- 38 during phase I trials
150. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients
151. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials
152. Irinotecan (CPT-11) metabolism and disposition in cancer patients
153. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer
154. Identification of a new metabolite of CPT-11 (irinotecan): Biosynthesis and activation to SN-38 by human hepatic microsomes
155. Phase I and pharmacokinetic study of irinotecan (CPT-11) in cancer patients with hepatic dysfunction
156. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients
157. 14C]CPT-11 in patients with advanced solid tumor malignancy
158. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
159. A pharmacokinetic study of CPT-11 and 5FU combination during a phase I trial
160. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
161. Irinotecan (CPT-11) in patients with advanced colon carcinoma (ACC) relapsing after 5-fluorouracil (5-FU)-leucovorin (LV) combination
162. Phase II study of irinotecan (CPT-11) in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil (5-FU) based chemotherapy: The experience of TTD Spanish Cooperative Group
163. Irinotecan (CPT-11) is effective as second-line chemotherapy in advanced colorectal cancer: A phase II trial of GISCAD (Italian Group for the Study of Gastrointestinal Cancer)
164. Phase II study of irinotecan as second line chemotherapy in metastatic colorectal cancer
165. Irinotecan (CPT-11) in patients with 5-FU refractory metastatic colorectal carcinoma
166. 5-FU-highly resistant advanced colorectal cancer patients treated with CPT-11: A phase II trial
167. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
168. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
169. A phase II study of irinotecan (CPT-11) as palliative therapy in refractory advanced colorectal cancer
170. Phase II trial of irinotecan (CPT-11) in patients with not pretreated advanced colorectal cancer
171. Phase II study of CPT-11, a new camptothecin derivative in metastatic colorectal cancer
172. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
173. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
174. Two different schedules of irinotecan (CPT-11) administration in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil (5-FU)-leucovorin (L) combination chemotherapy. Preliminary results of a randomized study
175. Recommended guidelines for the treatment of chemotherapy-induced diarrhea
176. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea
177. Phase III comparison of two dosing regimens (weekly × 4 every-6-weeks vs every-3-weeks) in second-line colorectal cancer
178. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5-FU failure
179. Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports
180. Bilirubin UDPglucuronyl-transferase gene promoter polymorphisms in a Hispanic population
181. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer
182. Combination of irinotecan with leucovorin and 5-FU in advanced colorectal carcinoma: A phase II study
183. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer
184. Randomized phase II study of irinotecan plus mitomycin (MMC) versus oxaliplatin plus MMC in patients with advanced fluoropyrimidine/leucovorinpretreated colorectal cancer (ACC)
185. A phase II multicenter trial of alternating cycles of irinotecan (CPT-11) and 5-FU/LV in patients with previously untreated metastatic colorectal cancer
186. A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer
187. First line chemotherapy with 5-fluorouracil (5-FU), leucovorin (LV) and irinotecan (CPT-11) in advanced colorectal cancer: A multicenter phase II study
188. Decrease of severe toxicities by reducing the 5-FU-dosage in the combination therapy with CPT-11/5-FU/FA weekly in patients with advanced colorectal cancer
189. Folinic acid (FA) and 5-fluorouracil/FU) alone or with irinotecan (CPT-11) for advanced colorectal cancer: Preliminary results of a randomized phase II trial
190. Irinotecan (CPT-11) with bolus 5-fluorouracil (5-FU) and folinic acid (FA) in patients with previously untreated metastatic colorectal cancer: An active and safe regimen
191. Irinotecan combined with fluorouracil compared with fluorouracil alone as firstline treatment for metastatic colorectal cancer: A multicentre randomised trial
192. First-line irinotecan (C) fluorouracil (F) leucovorin (L) especially improves survival (DS) in metastatic colorectal cancer (MCRC) patients (PT) with favorable prognostic indicators
193. Combined analysis of two phase III randomized trials comparing irinotecan (C), fluorouracil (F), leucovorin (L) vs F alone as first-line therapy of previously untreated metastatic colorectal cancer (MCRC)
194. Oxaliplatin: A new therapeutic option in colorectal cancer
195. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracilleucovorin as first-line treatment of metastatic colorectal cancer
196. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer